CClinicalTrials.gg
Sign In
CompletedNCT07251946Updated Nov 26, 2025

Development of Multiphasic CT-based Delta-Radiomics Model for Predicting Postoperative Recurrence Risk in Bladder Cancer

An observational study in Bladder Cancer, sponsored by Lian Yang. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Lian Yang · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
316
Ages
18 Years and older
Sex
All
01

Study summary

This retrospective study included 316 bladder cancer patients

02

Conditions studied

  • Bladder Cancer
03

In context

Urinary Bladder Neoplasms

1,616 studies on the registry are indexed under Urinary Bladder Neoplasms; 421 are open to participants now.

This study's enrollment of 316 is above the median of 180 across 374 observational studies indexed under Urinary Bladder Neoplasms.

Browse Urinary Bladder Neoplasms studies →

Lead sponsor

Lian Yang is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a confirmed diagnosis of bladder cancer

Inclusion criteria

  1. pathological diagnosis of bladder cancer,
  2. available clinical information,
  3. age >18 years,
  4. patients underwent non-contrast and enhanced abdominal CT examination within 4 weeks before cystectomy for bladder cancer.

Exclusion criteria

Exclusion Criteria:

  1. other malignancies in combination,
  2. less than one month of follow-up or lack of follow-up,
  3. patients with T4b stage,distant metastases (M1 stage)
  4. image artefacts or poor quality of image alignment.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
316 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. overall survival

    Time frame: 2 years

07

Study locations

1 site
  • Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07251946
Lead sponsor
Lian Yang
Responsible party
Lian Yang (Director, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Sponsor-investigator
First posted
Nov 26, 2025
Start date
Aug 1, 2019
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023
Last update
Nov 26, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Urinary Bladder Neoplasms→

Other studies from this sponsor

Lian Yang

Start the discussion